Daily10d
Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer
Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...
Merck, Moderna launch Phase 3 trial evaluating adjuvant V940, Keytruda combo
Merck (MRK) and Moderna (MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940, an ...
pharmaphorum4d
Merck and Moderna's mRNA cancer vaccine aces its first efficacy trial
The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
Why Is Moderna Stock Trading Higher On Monday?
On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...
Zacks.com on MSN22d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in ...
Hosted on MSN11d
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...
Merck cuts FY24 adjusted EPS view to $7.72-$7.77 from $7.94-$8.04
FY24 consensus $7.74. Narrows FY24 revenue view to $63.6B-$64.1B from $63.4B-$64.4B, consensus $64.15B. Published first on TheFly – the ...
Benzinga.com16d
Why Is Moderna Stock Trading Higher On Monday?
Also Read: Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target Merck and Moderna have initiated Phase 3 trials evaluating mRNA-4157 (V940 ...
AOL16d
Why Is Moderna Stock Trading Higher On Monday?
On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...